UNIT #2- video 6-Madera-Abuses-Dogs.m4v
News clip that demonstrates a truly abused (documented police case) puppy who is playful and has a happy temperament. By looking at this dog you #39;d never know he was abused. This video is used to demonstrate the human behavior where people misinterpret FEARFUL behavior in dogs and assume they are "abused." When a dog cowers in fear, it can be that the dog was NEVER abused at all, but that it simply has a skittish, fearful temperament due to genetics and puppyhood experiences. If you find a fearful dog, DO NOT ASSUME IT WAS ABUSED!! http://www.missingpetpartnership.org

By: pethunters

More:
UNIT #2- video 6-Madera-Abuses-Dogs.m4v - Video

Recommendation and review posted by Bethany Smith

UNIT #2 -Video 7-Abused-Pitbull.m4v
News story of physically abused pit bull. This video demonstrates that a bonafide abused dog might not LOOK abused--this dog is wiggly, friendly, happy and if not for the burn marks you #39;d not know this dog truly was abused. People who find skittish, fearful dogs often assume they are "abused" when in fact they are simply skittish, fearful dogs simply because they were born that way. Fearful behavior can be to genetics and puppyhood behavior, not necessarily because they were treated wrong.

By: pethunters

Originally posted here:
UNIT #2 -Video 7-Abused-Pitbull.m4v - Video

Recommendation and review posted by Bethany Smith

Dr Naresh Trehan explains the role of genetics in the possibility of a heart disease
Dr Naresh Trehan, leading Cardio Vascular Cardio Thoracic surgeon and the chairman of Medanta hospital explains if genetics and family history play a role in the possibility of a person getting heart disease.

By: wonderdoctorindia

Read more here:
Dr Naresh Trehan explains the role of genetics in the possibility of a heart disease - Video

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Jan 18, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that Kyle Guse, chief financial officer, general counsel and secretary, will present at the NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference held at the Hard Rock Hotel & Casino, Hollywood, Florida, on Tuesday, January 22, at 3:00 pm Eastern Time. A webcast of the presentation will be available on Atossa's web site at http://www.atossagenetics.com.

Mr. Guse stated, "I look forward to participating in this prestigious conference and presenting the Atossa Genetics story to investors. My presentation will include a discussion of the recently announced national rollout of our ForeCYTE Breast Health Test, further commercialization of our ArgusCYTE Breast Health Test, advancement of two additional tests and of the planned clinical development of our intraductal therapeutic for treatment of pre-cancerous cellular changes as a means to potentially prevent breast cancer."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission and other filings with the SEC.All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Go here to see the original:
Atossa Genetics, Inc. to Present at NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference

Recommendation and review posted by Bethany Smith

Until the very end of 2012, industry experts were predicting that the construction of new wind turbines for generating electricity would decline by as much as 90 percent in 2013. That was because a tax credit amounting to about $1 million dollars per windmill was set to expire on Dec. 31, 2012. Wind turbine developers rushed a lot of new wind turbines into production in 2012 in order to take advantage of the credit, but had essentially no plans for new construction in 2013. Had the tax credit actually expired, more than 30,000 jobs might have been lost in the industry.

But the industry got a last-minute reprieve as part of the fiscal cliff negotiations in the final days of 2012. Part of the tax package included in the final fiscal cliff deal was an extension of the tax credit for wind turbine construction that begins in 2013, provided that construction is completed by 2014. That gives the industry some breathing room, at least for now.

Federal tax credits are sometimes used to encourage the development of new industries that may not yet be cost-effective. The wind turbine industry has been granted tax credits three times since 1990. This time around, concerns over the national debt mean that there is likely to be very little enthusiasm in Congress for extending the subsidy (amounting to over a billion dollars a year) yet again after this one expires.

Currently, wind energy accounts for 23 percent of all electricity generated from renewable resources, according to government statistics. The other renewable energy sources are hydropower (63%), wood and biomass waste (11%), geothermal (3%), and solar.Source:
http://humanbiologyblog.blogspot.com/2013/01/wind-turbine-tax-credit-is-renewed.html

Recommendation and review posted by Bethany Smith

One of the defining features of humans is that the shape of our hands and fingers allows us to touch the tips of our fingers with our thumbs. As a result, we are able to pick up and manipulate very small objects – something other primates can’t do. Textbooks describe this human anatomical feature as having “opposable thumbs”. Allegedly it is a feature that has given us an evolutionary advantage.

Now researchers report that there’s another unique feature of the human hand that also confers an evolutionary advantage. According to a recent paper published in the Journal of Experimental Biology, the structural arrangement of the bones in the hand and the wrist allow us to make a very effective fist, for use as a weapon. The report demonstrates rather convincingly that when we curl the four fingers into the palm and then position the thumb over the index and second finger, the unique shape of the human fist allows the palm to buttress and support the fingers when we strike a blow. As a result, more force is transmitted by the knuckles than would be possible with the hand anatomy of other primates.

The authors of the study suggest that being able to use the fist as a weapon confers an evolutionary advantage. In other words, our hand evolved not only to be able to manipulate small objects easily, but also to fight effectively.Source:
http://humanbiologyblog.blogspot.com/2013/01/the-human-hand-makes-good-fist.html

Recommendation and review posted by Bethany Smith

Is it okay for pregnant women to get a flu shot? The answer is “yes”, according to a study conducted in Norway recently. (The research was conducted in Norway because access to health care in Norway is nearly universal, and good records are kept.) The results of the study are published in the New England Journal of Medicine. 

 The researchers reviewed the outcomes of the pregnancies of over 100,000 women in Norway during 2009 and 2010, about half of whom received the flu vaccine during the second or third trimester (the other half served as the control group). As expected, vaccination during pregnancy reduced the risk of getting the flu by about 70% compared to the control group. Vaccination during pregnancy also appeared to reduce the risk of fetal death slightly, but the reduction was not statistically significant.

Pregnant women tend to suffer more complications of the flu than non-pregnant women, in part because their immune systems are partially suppressed during pregnancy. So it’s important that they understand that they can get a flu shot without harming their babies. In fact, the flu vaccine may be good for the fetus/newborn as well as good for the mother; antibodies produced by the mother can cross the placenta (protecting the fetus) and are found in the mother’s milk (protecting the newborn for up to six months).Source:
http://humanbiologyblog.blogspot.com/2013/01/pregnancy-and-flu-vaccine.html

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Information ::: What You Need To Know
Random video I thought about making for awhile still not sure if I like it but ya xD Information about Spinal Cord Injury and pictures

By: Rachel Griffith

Original post:
Spinal Cord Injury Information ::: What You Need To Know - Video

Recommendation and review posted by sam

2 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
2 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Here is the original post:
2 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

4 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
4 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Here is the original post:
4 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

3 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
3 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Read more:
3 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

Dr. Charles Cantor at the First Open Institute for Regenerative Medicine for Young Scientists
1 out of 5 Regenerative Medicine and Cell Technology: My View on Some Future Trends by Professor Charles Cantor, CSO, Sequenom, Professor Boston University, Professor, University of California Irvine http://www.charlescantor.org http://www.facebook.com

By: antiaging

Here is the original post:
Dr. Charles Cantor at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7pv874/drug_delivery_in) has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.

Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.

Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.

Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.

The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2012-2022 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.

Profiles of 222 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 249 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 60 tables and 9 figures.

Key Topics Covered:

1. Introduction to cancer therapy

Read this article:
Research and Markets: Drug Delivery in Cancer - Technologies, Markets and Companies - 2013 Report

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/p6tm2n/rnai) has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2012 to 2022. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 229 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 34 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 34 tables and 11 figures.

Key Topics Covered:

Read the original:
Research and Markets: RNAi - Technologies, Markets and Companies - 2013 Report

Recommendation and review posted by Bethany Smith

New Delhi, Jan. 18: A promise of anonymity in genomic research may be misleading.

A new study has shown that it is possible to determine the identities of people who have anonymously contributed genetic material for research, exposing gaps in existing security structures for personal genetic information.

A team of US scientists has combined genomic information with Internet search tools and public databases to identify nearly 50 individuals in America who had provided their genetic material as participants in genomic studies.

The researchers used genetic markers found on the Y-chromosome, which moves from father to son to first infer the surnames of the individuals and then used several public databases to determine their identities. The study appears today in the US journal Science.

"Our results show it is possible to identify some individuals who may have wished to remain anonymous," said Yaniv Erlich, principal investigator at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and senior author of the study.

Erlich and his colleagues have not revealed the identities of these individuals but shared their methodology of breaching privacy with senior staff at the US National Institutes of Health before the publication of the research.

The researchers hope the study will stimulate debate and research on policy guidelines and security procedures to protect the privacy of genetic information that can potentially reveal health information about individuals.

"We don't want people to stop donating genetic material and we want the public sharing of data to continue," Erlich told The Telegraph. "This study was intended to help policy makers and individuals appreciate the benefits and the risks of releasing genetic data."

The Whitehead researchers used genetic markers called short-tandem ' repeats on the Y-chromosome or Y-STRs ' that can provide information on paternal lineages when combined with recreational genetic genealogy databases.

The scientists used the two largest public genetic genealogy databases 'www.ysearch.org and http://www.smgf.org ' that are free-of-charge and are equipped with search engines.

Original post:
Study exposes hole in gene security

Recommendation and review posted by Bethany Smith

Gene therapy PowerPoint Template - Gene therapy PowerPoint (PPT) Backgrounds Templates (Download)
Download - beefile.info/apps/download.php?dl=Gene-therapy-PowerPoint-Template---Gene-therapy-PowerPoint-(PPT)-Backgrounds-Templates

By: alan baumen

Read more from the original source:
Gene therapy PowerPoint Template - Gene therapy PowerPoint (PPT) Backgrounds Templates (Download) - Video

Recommendation and review posted by Bethany Smith

Local Non-Profit funds Cancer Research
Watch more and discuss: stamford.itsrelevant.com The Alliance for Cancer Gene Therapy has awarded millions to cancer research. The Stamford-based Alliance was founded by Greenwich residents Edward and Barbara Netter.

By: irstamford

More:
Local Non-Profit funds Cancer Research - Video

Recommendation and review posted by Bethany Smith

Opening of the Penn State Hershey Institute for Personalized Medicine
Opening of the Penn State Hershey Institute for Personalized Medicine View article at lancasteronline.com

By: lancasteronline

Excerpt from:
Opening of the Penn State Hershey Institute for Personalized Medicine - Video

Recommendation and review posted by sam

MANILA, Philippines --- The Department of Health (DOH) is preparing guidelines for the use of stem cell therapy in the treatment of diseases in the Philippines.

This was announced by DOH Secretary Enrique T. Ona yesterday in a convention on stem cell therapy at the Manila Hotel.

Ona said a bio-ethics advisory board will develop the guidelines which will include ethical standards in the application of stem cell therapy to treat diseases such as malignancies, blood disorders and metabolic disorders, among others.

"The institutional board will review and approve Stem Cell therapies based on guidelines by the advisory board," Ona said.

He added that the board will also include ethical and legal issues surrounding stem cell therapy.

Last week, the Philippine Medical Association (PMA) and the Philippine Society for Stem Cell Medicine (PSSCM) issued a joint statement that warned against the dangers of receiving stem cell transplants that came from another source other than the patient's body.

"If the stem cell that you received is not from your own body, it could lead to fatal complications," Philippine Society for Stem Cell Medicine (PSSCM) and the PMA said.

The doctors warned that complications arising from stem cell transplants include graft-versus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.

Ona said a public hearing will be held on January 18 regarding the preliminary draft of the guidelines.

He said the guidelines will ensure the minimum quality of service and application in the use of stem cells in health settings.

See the article here:
Stem Cell Therapy Guidelines Readied

Recommendation and review posted by Bethany Smith

SILVER SPRING, Md., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today that its technologies, Cell-in-a-Box(R) and Bac-in-a-Box(R), developed by its subsidiary Austrianova Singapore (ASPL), have been recognized and profiled by the non-profit company, Intellectual Property Intermediary Singapore (IPI Singapore).

The Cell-in-a-Box(R) and Bac-in-a-Box(R) products are proprietary living eukaryotic and bacterial cell encapsulation technological platforms developed by ASPL that can be used for a variety of living cell types. Both of them are unique platform technologies with the potential for such diverse uses as antibody production, treatment of diabetes, part of pancreatic cancer treatment regimen, treatments that employ stem cells, and for the improved use of probiotics, to name a few.

The technologies have been shown to be robust for manipulations and injections and are non-immunogenic. They can be frozen with cells inside that can be recovered years later, and they allow cells to be expanded inside the capsules as mini bioreactors. Moreover, the technology has been shown to be safe and effective for multiple diseases in animal models as well as in human clinical trials for pancreatic cancer.

IPI Singapore was launched in April 2011 as part of the Singapore Research, Innovation, and Enterprise 2015 Plan to contribute to the innovation and enterprise ecosystem in Singapore. IPI's overall aims include helping companies "identify, source, scan and assess technologies" as well as "facilitate technology transfer."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated, "We are pleased IPI Singapore has recognized our technology and will provide access to information about the technologies developed by our ASPL subsidiary. We believe our Company will receive increased exposure to the business and scientific communities due to the recognition by IPI Singapore. Through this recognition and our ongoing efforts, we hope to develop multiple unique products for commercialization from the Cell-in-a-Box(R) and Bac-in-a-Box(R) technology platforms."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, enhanced antibody production capabilities through encapsulation, our company's offerings will include cancer, diabetes, and other clinical treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

View post:
Nuvilex Technologies Recognized by the Singaporean Intellectual Property Intermediary, IPI Singapore

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8xfhl4/antiviral) has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.

A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed.

Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2012 with projections up to the year 2022.

Profiles of 178 companies that are involved in developing various technologies and products are profiled and with 167 collaborations. These include major pharmaceutical companies (13), Biopharmaceutical companies with antiviral products (80), Antiviral drug companies (25) as well as viral vaccine companies (60). The report is supplemented with 50 tables, 11 figures and 470 references from the literature.

Key Topics Covered:

Executive Summary

1. Introduction to Virology

2. Antiviral Approaches

Read the original here:
Research and Markets: Antiviral Therapeutics - Technologies, Markets and Companies - 2013

Recommendation and review posted by Bethany Smith

Jews of European origin are a mix of ancestries, with many hailing from tribes in the Caucasus who converted to Judaism and created an empire that lasted half a millennium, according to a gene study.

The investigation, its author says, should settle a debate that has been roiling for more than two centuries.

Jews of European descent, often called Ashkenazis, account for some 90 percent of the more than 13 million Jews in the world today.

According to the so-called Rhineland Hypothesis, Ashkenazis descended from Jews who progressively fled Palestine after the Moslem conquest of 638 AD.

They settled in southern Europe and then, in the late Middle Ages, about 50,000 of them moved from the Rhineland in Germany into eastern Europe, according to the hypothesis.

But detractors say this idea is implausible.

Barring a miracle --which some supporters of the Rhineland Hypothesis have in fact suggested -- the scenario would have been demographically impossible.

It would mean that the population of Eastern European Jews leapt from 50,000 in the 15th century to around eight million at the start of the 20th century.

That birth rate would have been 10 times greater than that of the local non-Jewish population. And it would have occurred despite economic hardship, disease, wars and pogroms that ravaged Jewish communities.

Seeking new light in the argument, a study published in the British journal Genome Biology and Evolution, compares the genomes of 1,287 unrelated individuals who hail from eight Jewish and 74 non-Jewish populations.

Continue reading here:
Gene study settles debate over origin of European Jews

Recommendation and review posted by Bethany Smith

People who have a certain variant of the ABCC11 gene don't produce under arm odor, though many of them still wear deodorant, Bristol University researchers report in the Journal of Investigative Dermatology. (The variant is also linked to dry earwax.)

Drawing on about 17,000 people from the Avon Longitudinal Study of Parents and Children study, the researchers investigate how having the ABCC11 rs17822931 variant affects people's hygiene behavior. People who are homozygotes for the rs17822931 A allele are five times less likely to use deodorant than GG homozygotes and heterozygotes are, they find.

However, the researchers note that nearly 80 percent of white European mothers in the study who, based on their genotype, should not produce under arm odor still wear deodorant and that that behavior is likely socially and culturally driven.

"This effect has a biological basis that can result in a change in the family's environment if an aerosol deodorant is used. It also indicates potential cost saving to the nonodorous and scope for personalized genetics usage in personal hygiene choices, with consequent reduction of inappropriate chemical exposures for some," the researchers add.

Read the original here:
The Deodorant Gene …

Recommendation and review posted by Bethany Smith

PARK CITY, Utah--(BUSINESS WIRE)--

Rejuvenation Labs today announced the launch of Resvology, the only topical anti-aging skin care line containing the multi-patented, gene-activating 4-AR Molecule, a uniquely stabilized ester form of the widely recognized youth molecule resveratrol.

Resvologys anti-aging effectiveness is based upon a proprietary molecule discovered by a team of cancer researchers at Brigham Young University working under a grant by the National Institutes of Health. Through in-vitro studies, the 4-AR Molecule (or resveratryl acetate) has been observed to activate 85 key skinrelated genes to fuel gene activity, including:

Unveiled at the Sundance Film Festival, the Resvology Age Corrective collection consists of three core products designed for all skin types: the Age Corrective Wrinkle Treatment, Age Corrective Eye Cream and the Gentle Cleansing Gel. These products work together to hydrate and smooth skin texture and reduce signs of aging, helping keep skin looking firm, lifted and youthful.

Researchers also observed a significant correlation between the 4-AR Molecule in higher production of several proteins and enzymes important to cell regeneration. In clinical trials, consumers have reported that Resvology hydrated skin, removed fine lines and wrinkles, and minimized puffiness and dark circles around the eyes.

The discovery of the 4-AR Molecule has improved our understanding of the skins aging process, and how it can look and feel more youthful, said Kevin Passey, CEO of Rejuvenation Labs. Resvology sets a new standard for anti-aging effectiveness in the skin care industry by creating the most stable and accessible use of resveratrol. Resvology will make a genuine difference in how women look and feel.

The science behind the 4-AR Molecule captured the early attention of entrepreneurs Gary Crocker and Dinesh Patel, two leading life science experts who have each founded numerous successful biotechnology companies. Crocker and Patel are members of the board of directors of Rejuvenation Labs, and together they are providing substantial financial backing for the launch of Resvology.

Crocker has founded multiple successful medical device companies, including Research Medical, which became the worlds largest supplier of cardiac bypass catheters before it was acquired by Baxter International for $250 million. Crocker is currently chairman of Merrimack Pharmaceuticals, a leader in oncology research and treatment, and CEO of Crocker Ventures. Patel, one of the leading fathers of biotechnology in the Mountain West region, has led or helped launch many companies. Holder of numerous patents, Patel was also CEO of Theratech, a leader in drug delivery technology that he co-founded with Crocker. Theratech was purchased by Watson Pharmaceuticals.

It is exciting to be part of a team of scientists and business leaders that are creating an innovative skin care line with observable results, said Crocker. The discovery of the 4-AR Molecule and the quality of the scientific and business teams made it clear that this is more than just another skin care line. Rejuvenation Labs will make a major impact in the beauty care market.

Resvology will roll out in the first quarter of 2013 and be sold at specialty retailers. For more information, visit http://www.resvology.com.

Originally posted here:
Resvology Launches Anti-Aging Skin Care Line with Patented Gene-Activating Molecule

Recommendation and review posted by Bethany Smith

Editor's Choice Academic Journal Main Category: Autism Also Included In: Genetics Article Date: 16 Jan 2013 - 12:00 PST

Current ratings for: New Gene Variants Linked To Autism Discovered

2 (1 votes)

The research team, led by Hakon Hakonarson, MD, PhD, explained in the journal PLOS ONE that they identified 25 additional copy number variants (CNVs) that occur in some people with autism. CNVs are duplicate or missing stretches of DNA.

They describe these copy number variants as individually rare, but of "high impact", meaning that each one has a strong effect in increasing a person's risk for autism.

Dr. Hakonarson said:

Scientists from the Seaver Autism Center at Icahn School of Medicine at Mount Sinai said that there are hundreds of mutated genes linked to ASDs.

In this study, the team initially analyzed the DNA of 55 people from families in Utah with multiple members who had been diagnosed with ASDs. The data from high-risk families had been collected by Mark Leppert, PhD. They identified 153 CNVs as potentially linked to autism.

The team wanted to look at these CNVs in a broader ASD population. They custom-designed a DNA array with probes for all 153 CNVs, as well as an additional 185 CNVs which had been linked to autism in previous studies. They gathered and examined all the data to determine how common all the CNVs were in 3,000 people with an ASD and 6,000 control subjects previously gathered in studies carried out at The Children's Hospital of Philadelphia.

The researchers found that:

Read the original:
New Gene Variants Linked To Autism Discovered

Recommendation and review posted by Bethany Smith